Market Research Industry Reports

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H1 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H1 2018

Summary

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Tyrosine-protein kinase ITK/TSK or interleukin-2-inducible T-cell kinase or simply ITK is a protein encoded by the ITK gene. It plays an essential role in regulation of the adaptive immune response. When antigen presenting cells (APC) activate T-cell receptor (TCR) a series of phosphorylation lead to the recruitment of ITK to the cell membrane, stimulate TCR receptor, where it is phosphorylated by LCK. Phosphorylation leads to ITK autophosphorylation and full activation. It regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells.

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) pipeline Target constitutes close to 9 molecules. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 3, 4 and 2 respectively.

Report covers products from therapy areas Immunology, Oncology, Dermatology, Gastrointestinal, Genetic Disorders and Respiratory which include indications Psoriasis, Metastatic Renal Cell Carcinoma, Rheumatoid Arthritis, Allergies, Angiosarcoma, Asthma, Atopic Dermatitis, Bile Duct Cancer (Cholangiocarcinoma), Chondrosarcoma, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Follicular Thyroid Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Inflammation, Liposarcoma, Merkel Cell Carcinoma, Metastatic Bile Duct Cancer, Metastatic Breast Cancer, Neuroblastoma, Osteosarcoma, Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Plaque Psoriasis (Psoriasis Vulgaris), Recurrent Glioblastoma Multiforme (GBM), Rhabdomyosarcoma, Soft Tissue Sarcoma, Thyroid Cancer, Ulcerative Colitis, Vitiligo and Von Hippel-Lindau Syndrome.

The latest report Tyrosine Protein Kinase ITKTSK - Pipeline Review, H1 2018, outlays comprehensive information on the Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Arrien Pharmaceuticals LLC
Corvus Pharmaceuticals Inc
Genentech Inc
Japan Tobacco Inc
Novartis AG
Principia Biopharma Inc
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Drug Profiles
ARN-4079 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNE-4997 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JTE-051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pazopanib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pazopanib hydrochloride + pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRN-694 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ITK and TXK for Psoriasis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ITK for Autoimmune Disorders, Chronic Inflammation and Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ITK for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Jul 21, 2016: Mateon Announces Enrollment of First Patient in Phase 2 Portion of PAZOFOS Study in Recurrent Ovarian Cancer
Mar 16, 2015: Cancer drug may reduce bleeding in patients with rare genetic disorder, HHT
Sep 01, 2014: Arrien Pharmaceuticals Provides Update on ARN-4079
Apr 01, 2014: Results from phase III patient preference study of GSKs Votrient (pazopanib) vs. Sutent (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology
Mar 31, 2014: Votrient as maintenance therapy for advanced ovarian cancer in the EU
Aug 21, 2013: Pazopanib shows better quality-of-life in advanced kidney cancer
Aug 07, 2013: GSK seeks additional indication approval for Votrient from EMA
Jul 11, 2013: GlaxoSmithKlines cancer drug Votrient receives full EU approval
Jun 01, 2013: GSKs Votrient Meets Primary Endpoint In Phase III Clinical Trial As Maintenance Therapy In Women With Advanced Epithelial Ovarian Cancer
Jan 08, 2013: Combination Of Pazopanib And Paclitaxel May Slow Anaplastic Thyroid Cancer, Mayo Clinic Study Shows
Oct 01, 2012: GlaxoSmithKlines Votrient Meets Primary Endpoint In Pivotal Phase III Study Of Advanced Renal Cell Carcinoma
Aug 07, 2012: GlaxoSmithKline Receives Marketing Authorization From European Commission For Pazopanib
May 25, 2012: GSK Receives Positive Opinion from European CHMP For Pazopanib In Treatment Of Patients With Certain Advanced Soft Tissue Sarcomas
Apr 26, 2012: GSKs Votrient Receives FDA Approval For Treatment Of Advanced Soft Tissue Sarcoma
Mar 20, 2012: GSK Announces Positive Vote From FDA Panel For Pazopanib In Certain Advanced Soft Tissue Sarcomas
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Aclaris Therapeutics Inc, H1 2018
Pipeline by Arrien Pharmaceuticals LLC, H1 2018
Pipeline by Corvus Pharmaceuticals Inc, H1 2018
Pipeline by Genentech Inc, H1 2018
Pipeline by Japan Tobacco Inc, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by Principia Biopharma Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018

List Of Figures

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Pipeline Review, H2 2018

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or

USD 3500View Report

Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) - Pipeline Review, H2 2018

Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or

USD 3500View Report

Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Pipeline Review, H2 2018

Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Pipeline

USD 3500View Report

Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Pipeline Review, H2 2018

Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44

USD 3500View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 3500
  • Site Licence    USD 7000
  • Enterprise Wide Licence    USD 10500
$ 3500

Reports Details

Published Date : Jun 2018
No. of Pages :56
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube